Inovio Pharmaceuticals, INC. 8-K Filing
Ticker: INO · Form: 8-K · Filed: Apr 2, 2026 · CIK: 0001055726
| Field | Detail |
|---|---|
| Company | Inovio Pharmaceuticals, INC. (INO) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2026 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $3.2 m |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Inovio Pharmaceuticals, INC. (ticker: INO) to the SEC on Apr 2, 2026.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (nge on which registered Common Stock, $0.001 par value INO The Nasdaq Stock Mark); $3.2 m (nt for aggregate gross sale proceeds of $3.2 million, before deducting sales commissio).
How long is this filing?
Inovio Pharmaceuticals, INC.'s 8-K filing is 2 pages with approximately 549 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2026-04-02 06:15:21
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value INO The Nasdaq Stock Mark
- $3.2 m — nt for aggregate gross sale proceeds of $3.2 million, before deducting sales commissio
Filing Documents
- d107839d8k.htm (8-K) — 23KB
- 0001193125-26-138870.txt ( ) — 134KB
- ino-20260401.xsd (EX-101.SCH) — 3KB
- ino-20260401_lab.xml (EX-101.LAB) — 18KB
- ino-20260401_pre.xml (EX-101.PRE) — 11KB
- d107839d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INOVIO PHARMACEUTICALS, INC. Date: April 2, 2026 By: /s/ Peter Kies Peter Kies Chief Financial Officer